ClinicalTrials.gg
Enrolling by invitationNCT06138808Updated Jun 5, 2026

5-SENSE Score Validation Study

An observational study in Epilepsy Intractable, sponsored by Duke University. Enrolling by invitation at 19 sites in 12 countries. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Duke University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Drug Resistant Epilepsy with a site in United States — 29 open to participants now, 34 under way, 2 of them phase 3. Drug Resistant Epilepsy · United States.

Started
2024
with 8 others
Observational
7 of 78
2 open now
Primary completion
2027-01
later than 10 of 33 live
Registered
53rd of 78
by date
Lead sponsor
4 of 78
Duke University

Among the 78 studies in Drug Resistant Epilepsy with a site in United States, this one is one of 9 that started in 2024, is one of 7 observational ones, reaches primary completion later than 10 of the 33 other live ones, and was the 53rd registered.

Drug Resistant Epilepsy

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

Browse Drug Resistant Epilepsy studies →

Open to participants now

29 of the 78 studies in Drug Resistant Epilepsy with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Drug Resistant Epilepsy with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess how well a new scoring system called the 5-SENSE score can predict where seizures start in the brain using Stereoelectroencephalography (SEEG). The 5-SENSE Score is a 5-point score based on routine presurgical work-up, designed to assist in predicting whether SEEG can identify a focal seizure onset zone, thereby sparing patients the risk of undergoing this invasive diagnostic procedure.

03

Conditions studied

  • Epilepsy Intractable

Keywords

  • epilepsy
  • surgery
  • stereo-electroencephalography
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients will be prospectively recruited at 20-25 epilepsy centers from North America, Europe, Australia and Asia.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients aged 15 years or older in whom no direct surgical approach can be offered and who are discussed in the multidisciplinary team discussion
  • availability of complete non-invasive presurgical work-up (including high-resolution MRI according to the in-center epilepsy protocol, video-telemetry with the recording of a minimum of one habitual clinic and EEG seizure, available as original files for review)

Exclusion criteria

Exclusion Criteria:

  • no telemetry/scalp EEG in center
  • no protocol MRI in center
  • subdural/GRID electrodes
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Stereoelectroencephalography (SEEG)

    Participants undergoing SEEG as part of standard of care.

    Other: Stereoelectroencephalography (SEEG)

  • Control Group

    Participants not undergoing SEEG as part of standard of care.

Interventions

  • OtherStereoelectroencephalography (SEEG)

    Participants will under Stereoelectroencephalography (SEEG) as part of standard of care. This is not assigned by the protocol.

06

What researchers measure

Primary outcomes

  1. Specificity of the 5-SENSE score for the identification of a focal SOZ on SEEG

    Prospective validation of the predictive value of the 5-SENSE score to identify a focal seizure onset zone (SOZ) in an independent patient sample. Measured for participants undergoing SEEG.

    Time frame: At time of SEEG, up to approximately 1 month

  2. Sensitivity of the 5-SENSE score for the identification of a focal SOZ on SEEG

    Prospective validation of the predictive value of the 5-SENSE score to identify a focal seizure onset zone (SOZ) in an independent patient sample. Measured for participants undergoing SEEG.

    Time frame: At time of SEEG, up to approximately 1 month

  3. Positive predictive value of the 5-SENSE score for the identification of a focal SOZ on SEEG

    Measured for participants undergoing SEEG

    Time frame: At time of SEEG, up to approximately 1 month

  4. Negative predictive value of the 5-SENSE score for the identification of a focal SOZ on SEEG

    Measured for participants undergoing SEEG

    Time frame: At time of SEEG, up to approximately 1 month

Secondary outcomes

  1. Specificity of the 5-SENSE score augmented by information from auxiliary diagnostic methods for the identification of a focal SOZ on SEEG

    For participants undergoing SEEG, information from auxiliary diagnostic methods, performed routinely during presurgical evaluation, namely FDG-PET, electrical source imaging (ESI) and/or magnetic source imaging (MSI) and ictal HMPAO-SPECT will be analyzed. The investigators will assess whether addition of those variables to the 5-SENSE Score could enhance score performance with higher specificity for identifying a focal SOZ

    Time frame: At time of SEEG, up to approximately 1 month

  2. Sensitivity of the 5-SENSE score augmented by information from auxiliary diagnostic methods for the identification of a focal SOZ on SEEG

    For participants undergoing SEEG, information from auxiliary diagnostic methods, performed routinely during presurgical evaluation, namely FDG-PET, electrical source imaging (ESI) and/or magnetic source imaging (MSI) and ictal HMPAO-SPECT will be analyzed. The investigators will assess whether addition of those variables to the 5-SENSE Score could enhance score performance with higher sensitivity for identifying a focal SOZ

    Time frame: At time of SEEG, up to approximately 1 month

  3. Concordance of the 5-SENSE Score with the decision whether to proceed with SEEG or not

    Before SEEG, the decision whether to proceed with SEEG or not is made blinded from the 5- SENSE Score in a Multidisciplinary Team Discussion (MTD). Following the decision, the 5-SENSE Score will be calculated for each participant by the principal investigator. Concordance of the 5-SENSE Score with the decision made in the MTD will be assessed.

    Time frame: At enrollment

07

Study locations

19 sites
  • University of Florida College of Medicine
    Gainesville, Florida 32610, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Duke University Health System
    Durham, North Carolina 27710, United States
  • Presbyterian-Shadyside Hospital
    Pittsburgh, Pennsylvania 15232, United States
  • Monash University
    Melbourne, Victoria 3800, Australia
  • Mater Health
    Brisbane, Australia
  • Alfred Health
    Melbourne, Australia
  • Christian Doppler University Hospital Paracelsus Medical University Salzburg and Centre for Cognitive Neuroscience Salzburg
    Salzburg, 5020, Austria
  • Dalhousie Universiry and Hospital
    Dalhousie, Nova Scotia, Canada
  • Wester University
    London, Ontario, Canada
  • Departmet of Neurology, Masaryk University Brno
    Brno, Czechia
  • Danish Epilepsy Centre, Aarhus Universitets Hospital
    Aarhus, 8200, Denmark
  • Grenoble Institute of Neurosciences, Centre Hospitalier Universitaire Grenoble Alpes
    Grenoble, France
  • Epilepsy Department University Hospitals of Marseille
    Marseille, France
  • Epilepsy Centre, University Hospital Freiburg
    Freiburg im Breisgau, Germany
  • University School of Medicine Kyoto
    Kyoto, 606-8303, Japan
  • "Carol Davila" University of Medicine and Pharmacy
    Bucharest, Romania
  • Hospital Universitario y Politecnico La Fe
    Valencia, Spain
  • Department of Clinical Neurosciences chez CHUV; Centre Hospitalier Universitaire Vaudois
    Lausanne, Switzerland
08

References and documents

Publications

  • Astner-Rohracher A, Ho A, Archer J, Bartolomei F, Brazdil M, Cacic Hribljan M, Castellano J, Dolezalova I, Fabricius ME, Garces-Sanchez M, Hammam K, Ikeda A, Ikeda K, Kahane P, Kalamangalam G, Kalss G, Khweileh M, Kobayashi K, Kwan P, Laing JA, Leitinger M, Lhatoo S, Makhalova J, McGonigal A, Mindruta I, Mizera MM, Neal A, Oane I, Parikh P, Perucca P, Pizzo F, Rocamora R, Ryvlin P, San Antonio Arce V, Schuele S, Schulze-Bonhage A, Suller Marti A, Urban A, Villanueva V, Vilella Bertran L, Whatley B, Beniczky S, Trinka E, Zimmermann G, Frauscher B. Prognostic value of the 5-SENSE Score to predict focality of the seizure-onset zone as assessed by stereoelectroencephalography: a prospective international multicentre validation study. BMJ Neurol Open. 2024 Aug 21;6(2):e000765. doi: 10.1136/bmjno-2024-000765. eCollection 2024. PubMed 39175939 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Jan 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2023
First posted
Nov 18, 2023
StartActual
Jan 9, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Jun 2027
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06138808
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Jan 9, 2024
Primary completion
Jan 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jun 5, 2026

Study contacts

Birgit Frauscher, MD PD
principal investigator · Duke University
Alexandra Astner-Rohracher
principal investigator · Christian Doppler University Hospital Paracelsus Medical University Salzburg and Centre for Cognitive Neuroscience Salzburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion